Colonic mucosal vasoactive intestinal peptide receptors in malformations of the enteric nervous system are reduced compared with morphologically normal innervated colon.

Schmittenbecher PP, Schuster F, Heinz-Erian P, Gais P

Pediatric surgery international1 May 2002Cited by 5 (Europe PMC)

PMID12021976DOI10.1007/s003830100687PepBankPUB-12021976

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

01HumanNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneObservational studyMechanism
In two hypoganglionosis biopsies, VIP receptor cover of the cell surface was the lowest of all groups (1.83%).
In plain wordsIn two gut biopsies with hypoganglionosis, VIP receptors were at the lowest level of all groups.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreaseMucosal VIP receptor cover in hypoganglionosis
Study
n = 2
Comparator
Morphologically normal innervated colon (4.31%)
Outcome group
Receptor activity and mechanism · Gastrointestinal
Measurements
VIP receptor cover of cell surface
1.83%
hypoganglionosis
Source sentences
Summary
The two HYP biopsies showed the lowest values (1.83%).
2 context sentences(design, population, supporting numbers)
Summary · context
VIP receptors covered 4.31% of the cell surface in MNIC.
Summary · context
Cryostat sections from 38 colonic biopsies (23 patients with AG, IND, or HYP, 15 with MNIC) were incubated with radioactive iodinated (125)I-VIP.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-1202197603
02HumanNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneObservational studyMechanism
In colonic biopsies, VIP receptor cover of the cell surface was lower in aganglionosis (2.72%) than in morphologically normal innervated colon (4.31%).
In plain wordsIn gut biopsies, aganglionosis was linked to fewer VIP receptors than in normal gut tissue.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreaseMucosal VIP receptor cover in aganglionosis
Study
n: not reported in source
Comparator
Morphologically normal innervated colon (4.31%)
Outcome group
Receptor activity and mechanism · Gastrointestinal
Measurements
VIP receptor cover of cell surface
2.72%
aganglionosis
Source sentences
Summary
The values were significantly reduced in AG (2.72%; #E5/E5#=0.012) and IND (2.93%; #E5/E5#=0.008).
2 context sentences(design, population, supporting numbers)
Summary · context
VIP receptors covered 4.31% of the cell surface in MNIC.
Summary · context
Cryostat sections from 38 colonic biopsies (23 patients with AG, IND, or HYP, 15 with MNIC) were incubated with radioactive iodinated (125)I-VIP.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-1202197601
03HumanNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneObservational studyMechanism
In colonic biopsies, VIP receptor cover of the cell surface was lower in intestinal neuronal dysplasia (2.93%) than in morphologically normal innervated colon (4.31%).
In plain wordsIn gut biopsies, intestinal neuronal dysplasia was linked to fewer VIP receptors than in normal gut tissue.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreaseMucosal VIP receptor cover in intestinal neuronal dysplasia
Study
n: not reported in source
Comparator
Morphologically normal innervated colon (4.31%)
Outcome group
Receptor activity and mechanism · Gastrointestinal
Measurements
VIP receptor cover of cell surface
2.93%
intestinal neuronal dysplasia
Source sentences
Summary
The values were significantly reduced in AG (2.72%; #E5/E5#=0.012) and IND (2.93%; #E5/E5#=0.008).
2 context sentences(design, population, supporting numbers)
Summary · context
VIP receptors covered 4.31% of the cell surface in MNIC.
Summary · context
Cryostat sections from 38 colonic biopsies (23 patients with AG, IND, or HYP, 15 with MNIC) were incubated with radioactive iodinated (125)I-VIP.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-1202197602
04HumanNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneObservational studyMechanism
In colonic biopsies, aganglionic colon could be distinguished from healthy proximal segments, and intestinal neuronal dysplasia from habitual constipation.
In plain wordsIn gut biopsies, aganglionic colon could be told apart from healthy proximal colon, and intestinal neuronal dysplasia from habitual constipation.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicableDistinction of aganglionic colon and neuronal dysplasia from comparison tissue
Study
n: not reported in source
Outcome group
Receptor activity and mechanism · Gastrointestinal
Source sentences
Summary
Aganglionic colon could be distinguished from healthy proximal segments and IND from habitual constipation.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-1202197604

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 12:41 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.